The Impact of Treatment Choice for Localized Prostate Cancer on Response to Phosphodiesterase Inhibitors

Analysis of these data suggests that choice of treatment for localized prostate cancer is unlikely to have a significant impact on response to phosphodiesterase type 5 inhibitors should they be needed after treatment. However, patients with better pretreatment sexual function are more likely to respond to phosphodiesterase type 5 inhibitors.